AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2507028 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment
Number of subjects: 61
Study 1256730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraamniotic prostaglandin F2alpha (PGF2alpha) and intracervical laminaria
Number of subjects: 116
Study 1256730 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin F2alpha (PGF2alpha) only
Number of subjects: 116
Study 31228196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics (nurse-delivered inpatient smoking cessation intervention)
Number of subjects: 1370
Study 31228196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1370
Study 30537271 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 0
Study 30537271 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 0
Study 27472299 — intervention group
Group type: EXPERIMENTAL
Intervention: HiFocusTM Mid-Scala (HFMS) electrode
Number of subjects: 19
Study 27472299 — intervention group
Group type: COMPARATOR
Intervention: HiFocusTM 1j (HF1j) electrode
Number of subjects: 19
Study 26048319 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 280
Study 23507723 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher positive end-expiratory pressure (12 ± 2 cm H2O)
Number of subjects: 10
Study 23507723 — intervention group
Group type: COMPARATOR
Intervention: Lower positive end-expiratory pressure (7 ± 2 cm H2O)
Number of subjects: 10
Study 23507723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower pressure support ventilation (3 ± 2 cm H2O)
Number of subjects: 10
Study 23507723 — intervention group
Group type: COMPARATOR
Intervention: Resting pressure support ventilation (12 ± 3 cm H2O)
Number of subjects: 10
Study 23507723 — intervention group
Group type: EXPERIMENTAL
Intervention: PaO2/FIO2 ratios
Number of subjects: 10
Study 21558030 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Strength Training (ST) for 12 weeks
Number of subjects: 30
Study 21558030 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Walking Training (WT) for 12 weeks
Number of subjects: 30
Study 20006031 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted anorectal pull through (LAARP)
Number of subjects: 23
Study 20006031 — intervention group
Group type: COMPARATOR
Intervention: Posterior sagittal anorectoplasty (PSARP)
Number of subjects: 23
Study 16022803 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically stimulated gracilis neosphincter surgery (ESGNS)
Number of subjects: 0
Study 16022803 — intervention group
Group type: COMPARATOR
Intervention: Comparison groups (not undergoing ESGNS)
Number of subjects: 0
Study 12137822 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (group 1)
Number of subjects: 187
Study 12137822 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic block of the prostatic plexus (group 2)
Number of subjects: 187
Study 12137822 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia onto the capsula of the apex (group 3)
Number of subjects: 187
Study 12137822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anesthesia used for groups 2 and 3 (group 4)
Number of subjects: 187
Study 10102792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg rhIL-10
Number of subjects: 12
Study 10102792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7775629 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms EE plus 3 mg DRSP (group A)
Number of subjects: 80
Study 7775629 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms EE plus 3 mg DRSP (group B)
Number of subjects: 80
Study 7775629 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms EE plus 3 mg DRSP (group C)
Number of subjects: 80
Study 7775629 — intervention group
Group type: COMPARATOR
Intervention: 30 micrograms EE plus 150 micrograms levonorgestrel (Microgynon, group D)
Number of subjects: 80
Study 2407755 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 52
Study 2407755 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 52
Study 2407755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 7457946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate (0.0015, 0.003, 0.006 mg/kg)
Number of subjects: 0
Study 7457946 — intervention group
Group type: COMPARATOR
Intervention: Morphine chlorhydrate (0.100, 0.150, 0.200 mg/kg)
Number of subjects: 0
Study 7457946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate
Number of subjects: 0
Study 7457946 — intervention group
Group type: COMPARATOR
Intervention: Morphine chlorhydrate
Number of subjects: 0
Study 31051279 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted seasonal trivalent inactivated influenza vaccine (aIIV3)
Number of subjects: 373
Study 31051279 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted inactivated influenza vaccine (IIV3)
Number of subjects: 373
Study 28080325 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed lunches
Number of subjects: 607
Study 28080325 — intervention group
Group type: COMPARATOR
Intervention: Consumed lunches
Number of subjects: 607
Study 26092515 — intervention group
Group type: EXPERIMENTAL
Intervention: silexan® (WS® 1265, lavender oil)
Number of subjects: 12
Study 26092515 — intervention group
Group type: EXPERIMENTAL
Intervention: WS® 5570 (Hypericum extract)
Number of subjects: 12
Study 26092515 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761® (Ginkgo biloba extract)
Number of subjects: 12
Study 23765693 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific enteral nutrition Supportan® containing EPA+DHA
Number of subjects: 111
Study 23765693 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (control group)
Number of subjects: 111
Study 22082794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all training methods (A)
Number of subjects: 65
Study 22082794 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance training using full-squat exercise (B)
Number of subjects: 65
Study 22082794 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-oriented strength training using parallel-squat exercise (C)
Number of subjects: 65
Study 22082794 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-oriented strength training using loaded countermovement jumping (D)
Number of subjects: 65
Study 22082794 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric jumping (E)
Number of subjects: 65
Study 19523796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 921
Study 19523796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study 17846072 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 17846072 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 30
Study 15217304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (0.1 mg/kg)
Number of subjects: 40
Study 15217304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxycodone (0.1 mg/kg)
Number of subjects: 40
Study 15217304 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal oxycodone (0.1 mg/kg)
Number of subjects: 40
Study 15217304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric oxycodone (0.1 mg/kg)
Number of subjects: 40
Study 11802453 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling (one brief individual counseling session and 4 follow-up telephone calls)
Number of subjects: 228
Study 9611670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.12 mg/kg bolus and 0.65 mg/kg/hour)
Number of subjects: 10
Study 9611670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 7922759 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg of artemisinine daily for 5 days
Number of subjects: 27
Study 7922759 — intervention group
Group type: COMPARATOR
Intervention: 750 mg of mefloquine plus 45 mg of primaquine as a single dose
Number of subjects: 27
Study 7922759 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 2838294 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone
Number of subjects: 80
Study 2838294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone and prochlorperazine
Number of subjects: 80
Study 29393818 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group I)
Number of subjects: 75
Study 29393818 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of 0.75% ropivacaine (group II)
Number of subjects: 75
Study 29393818 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of 0.75% ropivacaine with 100 μg fentanyl (group III)
Number of subjects: 75
Study 28594758 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion of etonogestrel implant (up to 48 hours postpartum)
Number of subjects: 100
Study 28594758 — intervention group
Group type: COMPARATOR
Intervention: Conventional insertion of etonogestrel implant (at 6 weeks postpartum)
Number of subjects: 100
Study 28594758 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion of etonogestrel implant
Number of subjects: 100
Study 28594758 — intervention group
Group type: COMPARATOR
Intervention: Conventional insertion of etonogestrel implant
Number of subjects: 100
Study 25268386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate (100 mg bid; total dose of 200 mg)
Number of subjects: 9
Study 25268386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate pretreatment (100 mg tid for three days)
Number of subjects: 9
Study 25268386 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg) alone
Number of subjects: 9
Study 24030452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupressure (EAP) for smoking cessation, treated once a week for 8 weeks after a 2-week run-in period.
Number of subjects: 0
Study 24030452 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific EAP treatments, treated once a week for 8 weeks after a 2-week run-in period.
Number of subjects: 0
Study 21935818 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point injection combined with stabilization splint (SS) therapy
Number of subjects: 50
Study 21935818 — intervention group
Group type: COMPARATOR
Intervention: Stabilization splint (SS) therapy
Number of subjects: 50
Study 18066916 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 140
Study 18066916 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed message
Number of subjects: 140
Study 16875158 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 million KIU aprotinin
Number of subjects: 91
Study 16875158 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 million KIU aprotinin
Number of subjects: 91
Study 16875158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 12228010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) by needle
Number of subjects: 0
Study 12228010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) by jet injection (Biojector®)
Number of subjects: 0
Study 12228010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular/intradermally (ID) by jet injection
Number of subjects: 0
Study 12228010 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11910660 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen 0.625 mg, selective estrogen receptor modulator (two doses), or placebo
Number of subjects: 48
Study 11910660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy and endometrial biopsy
Number of subjects: 48
Study 7473012 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (S)
Number of subjects: 122
Study 7473012 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus tetracycline fiber for 10 days (SF)
Number of subjects: 122
Study 7473012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber therapy alone for 10 days (F)
Number of subjects: 122
Study 7473012 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 10‐day serial fiber applications (FF)
Number of subjects: 122
Study 7473012 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 122
Study 1683184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30
Study 1683184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 30
Study 1683184 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 6800809 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine (1200 mg daily for 14 days)
Number of subjects: 7
Study 6800809 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (100 mg daily for 14 days)
Number of subjects: 7
Study 6800809 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (1200 mg daily for 14 days)
Number of subjects: 7
Study 6800809 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (1200 mg daily for 14 days) with injected 125I-T4
Number of subjects: 7
Study 31483961 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE-217 (30 mg once daily)
Number of subjects: 89
Study 31483961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 27278394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar sealer (BS group)
Number of subjects: 50
Study 27278394 — intervention group
Group type: COMPARATOR
Intervention: Standard electrocautery (control group)
Number of subjects: 50
Study 25495357 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification (low-intensity)
Number of subjects: 222
Study 25495357 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification (high-intensity)
Number of subjects: 222
Study 25495357 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.30 mg/kg)
Number of subjects: 222
Study 25495357 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.60 mg/kg)
Number of subjects: 222
Study 25495357 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 222
Study 24119607 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + adrenaline
Number of subjects: 140
Study 24119607 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Prilocaine
Number of subjects: 140
Study 24119607 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine
Number of subjects: 140
Study 24119607 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Saline (Control)
Number of subjects: 140
Study 21306863 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic acupressure at the LI4 acupoint
Number of subjects: 77
Study 21306863 — intervention group
Group type: COMPARATOR
Intervention: Sham site
Number of subjects: 77
Study 20031860 — intervention group
Group type: COMPARATOR
Intervention: No angina (score 100)
Number of subjects: 5460
Study 20031860 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly angina (score 61 to 99)
Number of subjects: 5460
Study 20031860 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly angina (score 31 to 60)
Number of subjects: 5460
Study 20031860 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily angina (score 0 to 30)
Number of subjects: 5460
Study 18187379 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (classical hemodynamic criteria)
Number of subjects: 100
Study 18187379 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (LVEF, FS, CI values)
Number of subjects: 100
Study 18187379 — intervention group
Group type: COMPARATOR
Intervention: LVEF >30%
Number of subjects: 100
Study 18187379 — intervention group
Group type: COMPARATOR
Intervention: FS >20%
Number of subjects: 100
Study 18187379 — intervention group
Group type: COMPARATOR
Intervention: CI >2.4 L/min per m2
Number of subjects: 100
Study 14966771 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (EX, n=19) for 3 months, mainly isokinetic (hydraulic) ergometry.
Number of subjects: 39
Study 14966771 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON, n=20).
Number of subjects: 39
Study 11533838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 50
Study 11533838 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 50
Study 11533838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HFOV and SIMV
Number of subjects: 50
Study 10695642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 28
Study 10695642 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine, 300 mg/day
Number of subjects: 28
Study 9094048 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful electrical stimulation of the sural nerve
Number of subjects: 6
Study 9094048 — intervention group
Group type: COMPARATOR
Intervention: Weak electrical stimulation of the sural nerve
Number of subjects: 6
Study 8251268 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 100 micrograms kg‐1 every 5 min to a total dose of 500 micrograms kg‐1
Number of subjects: 30
Study 8251268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms kg‐1 every 7 min to a total dose of 50 micrograms kg‐1
Number of subjects: 30
Study 8251268 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg kg‐1 for induction and 0.5 mg kg‐1 every 15 min to a total dose of 3 mg kg‐1
Number of subjects: 30
Study 3103336 — intervention group
Group type: EXPERIMENTAL
Intervention: polychemotherapy
Number of subjects: 102
Study 3103336 — intervention group
Group type: EXPERIMENTAL
Intervention: chemoimmunotherapy
Number of subjects: 102
Study 3103336 — intervention group
Group type: COMPARATOR
Intervention: untreated control
Number of subjects: 102
Study 29226862 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg encapsulated generic losartan once daily for 12 months
Number of subjects: 228
Study 29226862 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 months
Number of subjects: 228
Study 27129907 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Traction (MT)
Number of subjects: 72
Study 27129907 — intervention group
Group type: COMPARATOR
Intervention: Traction Table (TT)
Number of subjects: 72
Study 24512656 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 166
Study 24512656 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 166
Study 22499458 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal contact source
Number of subjects: 1680
Study 22499458 — intervention group
Group type: EXPERIMENTAL
Intervention: Media and conferences
Number of subjects: 1680
Study 22499458 — intervention group
Group type: COMPARATOR
Intervention: Hospital and GP sources
Number of subjects: 1680
Study 22499458 — intervention group
Group type: COMPARATOR
Intervention: Health care services
Number of subjects: 1680
Study 22499458 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital outpatients clinics
Number of subjects: 1680
Study 22499458 — intervention group
Group type: EXPERIMENTAL
Intervention: Public conferences
Number of subjects: 1680
Study 22499458 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinating center of Toulouse
Number of subjects: 1680
Study 20347144 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionals' contemporaneous notes of child abuse interviews
Number of subjects: 107
Study 20347144 — intervention group
Group type: EXPERIMENTAL
Intervention: Various layout styles for note taking
Number of subjects: 107
Study 18528313 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine acupuncture
Number of subjects: 56
Study 18528313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 56
Study 18528313 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 15508021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl self-administration (SA) 1.5 mg/70 kg
Number of subjects: 8
Study 15508021 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl passive administration (PA) 1.5 mg/70 kg
Number of subjects: 8
Study 15508021 — intervention group
Group type: COMPARATOR
Intervention: Naloxone pretreatment
Number of subjects: 8
Study 12420568 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH composite resin
Number of subjects: 4
Study 12420568 — intervention group
Group type: COMPARATOR
Intervention: Fuji II
Number of subjects: 4
Study 12420568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 4
Study 12420568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 4
Study 12420568 — intervention group
Group type: EXPERIMENTAL
Intervention: All four materials
Number of subjects: 4
Study 10516750 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-M0 patients
Number of subjects: 16
Study 10516750 — intervention group
Group type: COMPARATOR
Intervention: Adults with AML-M0
Number of subjects: 16
Study 10516750 — intervention group
Group type: COMPARATOR
Intervention: Pediatric patients with AML-M0
Number of subjects: 16
Study 8543502 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 40 mg/kg 8-hourly, up to a maximum of 6 g/day (n = 28)
Number of subjects: 56
Study 8543502 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (n = 17) or Ceftriaxone (n = 11)
Number of subjects: 56
Study 8543502 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 56
Study 8543502 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime or Ceftriaxone
Number of subjects: 56
Study 1674589 — intervention group
Group type: EXPERIMENTAL
Intervention: gp160 vaccine administered on days 0, 30, and 120 or on days 0, 30, 60, 120, 150, and 180
Number of subjects: 30
Study 1674589 — intervention group
Group type: EXPERIMENTAL
Intervention: gp160 vaccine with six injections
Number of subjects: 30
Study 1674589 — intervention group
Group type: COMPARATOR
Intervention: gp160 vaccine with three injections
Number of subjects: 30
Study 1674589 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count before vaccination
Number of subjects: 30
Study 1674589 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to vaccination
Number of subjects: 30